ProCE Banner Activity

Phase II MONARCH 1: CDK4/6 Inhibitor Abemaciclib in HR+/HER2- MBC After Chemotherapy

Slideset Download
Conference Coverage
Abemaciclib monotherapy was active in patients with heavily pretreated HR+/HER2- MBC and showed no new safety signals.

Released: June 06, 2016

Expiration: June 05, 2017

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

Amgen, Inc.

Ariad

Bayer Healthcare Pharma

Celgene

Genentech Roche Virology

Incyte

Merck Oncology

Taiho Pharmaceuticals